Pharma Looks to Inflammasome Inhibitors as All-Around Therapies

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

Written byRachael Moeller Gorman
| 23 min read

Register for free to listen to this article
Listen with Speechify
0:00
23:00
Share

ABOVE: Once activated, the NLRP3 inflammasome (illustrated) triggers a suite of pathways that may play an important role in many different diseases.
ARTWORK REPRODUCED WITH PERMISSION FROM PROFESSOR KATE SCHRODER, THE UNIVERSITY OF QUEENSLAND

Every morning of his life, no matter what he did, a young British man woke up with a fever, a headache, a rash on his trunk and limbs, joint pain, and ever-worsening deafness. His doctors had diagnosed him with a rare illness called Muckle-Wells syndrome, in which chronic inflammation rages out of control; no treatment had been able to cure his symptoms.

Then, in 2001, researchers in California discovered the genetic explanation for his disease: a mutation in a gene called CIAS1 (since renamed NALP3 and then NLRP3), which was later found to cause the resulting protein to be constantly activated. Around the same time, a group of scientists at the University of Lausanne in Switzerland found ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After earning a bachelor’s degree in biology and neuroscience from Williams College, Rachael spent two years studying the tiny C. elegans worm as a lab tech at Massachusetts General Hospital/Harvard University. She then returned to school to get a master’s degree in environmental studies from Brown University, and subsequently worked as an intern at Scientific AmericanDiscover magazine, and the Annals of Improbable Research, the originators of the yearly Ig Nobel prizes. She now freelances for both scientific and lay publications, and loves telling the stories behind the science. Find her at rachaelgorman.com or on Instagram @rachaelmoellergorman.

    View Full Profile

Published In

April 2021

Advancing Against Metastasis

Cancer cells can spread early and lie dormant for years

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform